||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Reneuron Share Discussion Threads
Showing 13901 to 13923 of 13925 messages
|positive - hopefully attract some interest from other investors pushing up the SP!|
|Michael Hunt, CFO of ReNeuron Group (RENE) (LSE:RENE) will be giving a briefing at the Shares Investor Evening on 27th October 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by AJ Bell Youinvest.
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development.
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.
The Shares event offers a unique opportunity to hear about the latest plans and strategy from the Directors of UK listed companies and Fund Managers, attendees can personally put forward questions to the presenters. The event will take place at the Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR. Registration begins at 18.00 and presentations at 18.30, followed by a drinks reception where attendees can mingle with the speakers and fellow investors.
Companies presenting at the event include:
Berkeley Energia (BKY)
ReNeuron Group (RENE)
Sphere Medical (SPHR)
+ more to be announced|
|Edison update c/o mol iii site
have updated their website 11/10/16
whilst nothing new for perhaps most posting/reading this bb
a reminder for any one new - extract
Stroke is a high-risk indication, but ReNeuron is attempting to demonstrate a meaningful reduction in disability that would offer a compelling case for further development and/or partnering (Phase IIa data in Q416 will determine next steps). The hRPC programme has Orphan (EU/US) and Fast Track (US) designation with a potentially pivotal Phase II/III study planned for 2017.
i also expect an interview re the stem cell meeting on the mesa 2016 to be available within the next few weeks|
|ReNeuron CFO Michael Hunt will be presenting to investors at the Proactive One2One forum on the evening of 20th October in Mayfair, London. For more details and to register please click here: http://tinyurl.com/jytrhr3|
How are you reading the stagnant state of affairs? does not sound like there are any earthshaking cures coming out of the stable. Masses of alternative work done internationally some with results, in Parkinson, Alzheimer and even stroke. I was expecting by now to see signs that say definitely hopeful to exciting. Neutral to mildly maybe positive is on the slate so far.|
|Good evening Algernon. Great article all very positive. It was posted on 6th September. Clearly hasn't been appreciated by the market yet. A bit like Doubting Thomas....need to see the evidence....so watch this space December and in the meantime lap up cheap stock. Best wishes And have a great weekend. Freddie|
|" ReNeuron Group will hit "milestone" with results next year, says CEO.."
Sorry can't post the link: what have they done?
It's on proactive investors: it says:
"..ReNeuron Group Plc (LON:RENE) expects first results in December from the current dosing trial of its flagship stem cell product CTX.
All patients have now been treated in the Phase II clinical study, which is aimed at sufferers of motor disability as a result of an ischaemic stroke.
The three month follow-up data will be a “key clinical milestone” said the group.
If successful, application for a Phase II/III controlled efficacy trial for CTX will be filed early in 2017.
"Our therapeutic development programmes remain on track with the next key clinical milestone being Phase II data from the PISCES II study in disabled stroke patients, due in December of this year,” said chief executive officer Olav Hellebø.
Elsewhere, its CTX cell therapy candidate for critical limb ischaemia (CLI) is currently in a Phase I clinical trial in the UK.
CLI is a condition that results in loss of blood flow to the lower limb that can lead to amputation, common in diabetics.
“ReNeuron remains well-funded to advance all of its therapeutic programmes through to further significant clinical milestones and we look forward to reporting further progress in the months ahead,” added Hellebø."|
|Ignore the spread of 2.5 - 2.75p
As you can currently buy at 2.525....I know!
Guess Aviva is rounding off.
Best wishes. Freddie|
|Hi John. Trouble is Woodford cannot increase his stake. We need a bull market and therefore it's groundbreaking news thats going to move us back up and beyond.
Tick tock etc
|A bit of positive news from the clinical trials and I think Mr Woodford will hoover up everything sub 5p to average down. So sleep easy tonight Freddie.|
|Either waytoday's thin trading may suggest it's over. Fingers crossed. Best wishes. Freddie|
|Hi john. You could well be right but judging by this mornings thin trading its hopefully finished. Fingers crossed. Freddie|
|Looks like a sale to me Freddie. The Reneuron website has been updated to reflect the overall percentage change in holding.|
|For info from iii site ref rns...
Orangemaker post......Was this actually a sale ? from the RNS it looks like a transfer of 20m shares from direct to indirect and my conclusion was that the 2.50 price was a mid price to reflect it.
Fredd1eboy reply.......Wish I knew more about how it all works because, if you're right OM and I have no reason to doubt you, I feel even better about the entire matter. Best wishes and thanks for the advise.|
|RNS identifies sellers...
Looks like 20m sold off equating to around £0.5m.
Lets hope that's the end of it, but I'm not holding my breath yet.
|Loads of buys showing at 2.5p so yes looks like good price indeed|
|Hope so. Just bought some more. Silly old me!|
|Hope you're right Rich. Looks like today's trading is still following the downward trend. I just cannot second guess what's going on. Oh well. Time will tell. Messa conference tomorrow so wait and see if any snippets are to be released. Best wishes. Freddie|
|Even a longterm biotech failure like VAL has jumped nearly 90% in last month...RENE day must be coming :)|
|All they need just now is to tell us that the techy is not making it's target pointers and like Renovo a couple of years ago - sorry chaps we're closing down and turning into a lending house with the cash. Oh, and forget about all the very expensive IP we said was in the pipeline it's all no use, and we're not going to tell you who we gave it to (oops - sold it to) and how much we were paid and who got paid for it.
'Spose it's not what we know,....|
|A question for the experts....
My Rene RSI indicator is showing zero for the past few days. I understand that any number below 30 is over sold and above 70 is over bought.
With recent volumes being so low does the indicator actually mean anything?
A bit like British Bulls low volume forecasts for Rene providing the prediction after the event?
|i expect great results from the treatments based upon the first SAFETY clinical trials and dont understand that the share price didnt move on the safety results! AIMHO|
|spot on john. plenty of news due soon...Ren001, Ren009 promised then followed by exosome, new manufacturing facility licensing, Ren003.
Best wishes Freddie
ps... wish I had kept some sareum rather than sell and buy more Rene with the proceeds.
Hindsight's a great thing!!!!!|